EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II

Jiayan Huang iD, Ezgi Caliskan Guzelce iD, Shadi K Gholami iD, Kara L Gawelek, Richard N Mitchell, Luminita H Pojoga, Jose R Romero, Gordon H Williams, Gail K Adler

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jiayan Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertension, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health National Heart, Lung, and Blood Institute, National Institute of Health National Heart, Lung, and Blood, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney injury molecule-1 (KIM-1) is a biomarker of renal injury and a predictor of cardiovascular disease. Aldosterone, via activation of the mineralocorticoid receptor, is linked to cardiac and renal injury. However, the impact of mineralocorticoid receptor activation and blockade on KIM-1 is uncertain. We investigated whether renal KIM-1 is increased in a cardiorenal injury model induced by L-NAME/ANG II, and whether mineralocorticoid receptor blockade prevents the increase in KIM-1. Since statin use is associated with lower aldosterone, we also investigated whether administering eiSther a lipophilic statin (simvastatin) or a hydrophilic statin (pravastatin) prevents the increase in renal KIM-1. Female Wistar rats (8–10 week old), consuming a high salt diet (1.6% Na+), were randomized to the following conditions for 14 days: control; L-NAME (0.2 mg/mL in drinking water)/ANG II (225 ug/kg/day on days 12–14); L-NAME/ANG II + eplerenone (100 mg/kg/day p.o.); L-NAME/ANG II + pravastatin (20 mg/kg/day p.o.); L-NAME/ANG II + simvastatin (20 mg/kg/day p.o.). Groups treated with L-NAME/ANG II had significantly higher blood pressure, plasma and urine aldosterone, cardiac injury/stroke composite score, and renal KIM-1 than the control group. Both eplerenone and simvastatin reduced 24-h urinary KIM-1 (p = 0.0046, p = 0.031, respectively) and renal KIM-1 immunostaining (p = 0.004, p = 0.037, respectively). Eplerenone also reduced renal KIM-1 mRNA expression (p = 0.012) and cardiac injury/stroke composite score (p = 0.04). Pravastatin did not affect these damage markers. The 24-h urinary KIM-1, renal KIM-1 immunostaining, and renal KIM-1 mRNA expression correlated with cardiac injury/stroke composite score (p < 0.0001, Spearman ranked correlation = 0.69, 0.66, 0.59, respectively). In conclusion, L-NAME/ANG II increases renal KIM-1 and both eplerenone and simvastatin blunt this increase in renal KIM-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionStrokeAnimalsFemaleRatsAldosteroneAngiotensin IIBlood PressureEplerenoneHepatitis A Virus Cellular Receptor 1KidneyNG-Nitroarginine Methyl EsterPravastatinRats, WistarReceptors, MineralocorticoidRNA, MessengerSimvastatin

Stichwörter der Autor:innen

CVD (cardiovascular disease)N-omega-nitro-L-arginine methyl ester (L-NAME)angiotensin II (ANG II)kidney injury molecule (KIM-1)mineralocorticoid receptor (MR)pravastatinsimvastatinstatin

Substanzen

AldosteroneAngiotensin IIEplerenoneHepatitis A Virus Cellular Receptor 1Hydroxymethylglutaryl-CoA Reductase InhibitorsNG-Nitroarginine Methyl EsterPravastatinReceptors, MineralocorticoidRNA, MessengerSimvastatin

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Jiayan Huang, Ezgi Caliskan Guzelce, Shadi K Gholami

Förderung

  • National Institute of Health National Heart, Lung, and Blood Institute
  • National Institute of Health National Heart, Lung, and Blood
  • NHLBI NIH HHS

Zitieren

APA

Huang, J., Caliskan Guzelce, E., Gholami, S. K., Gawelek, K. L., Mitchell, R. N., Pojoga, L. H., Romero, J. R., Williams, G. H., & Adler, G. K. (2023). Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076500

Vancouver

Huang J, Caliskan Guzelce E, Gholami SK, Gawelek KL, Mitchell RN, Pojoga LH, et al. Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076500

BibTeX
@article{Huang2023,
  author = {Huang, Jiayan and Caliskan Guzelce, Ezgi and Gholami, Shadi K and Gawelek, Kara L and Mitchell, Richard N and Pojoga, Luminita H and Romero, Jose R and Williams, Gordon H and Adler, Gail K},
  title = {Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076500}
}
Kostenlos starten →